Accord Healthcare Recalls Cinacalcet Tablets Due to Nitrosamine Contamination
Accord Healthcare is recalling Cinacalcet 30mg tablets nationwide due to a nitrosamine impurity (N-nitroso-cinacalcet) exceeding acceptable daily intake limits. Patients should consult their healthcare provider to confirm if their medication is affected.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for a pharmaceutical contaminant (nitrosamine) exceeding acceptable daily intake limits. No reported illnesses or injuries are stated in the source, making the hazard theoretical rather than realized, which caps the score at 3 per the rubric.
Plain-English summary
Accord Healthcare, Inc. is recalling Cinacalcet 30mg tablets in a nationwide recall in the United States and Puerto Rico. The affected product is available in two package sizes: 30 tablets per bottle (NDC: 16729-440-10) and 90 tablets per bottle (NDC: 16729-440-15).
The recall is due to Current Good Manufacturing Practice (CGMP) deviations involving the detection of a nitrosamine impurity, N-nitroso-cinacalcet, present in the product at levels exceeding the acceptable daily intake (ADI) limit.
Patients taking Cinacalcet from the affected lot numbers should contact their healthcare provider or pharmacist to determine if their medication is included in the recall. Patients should not stop taking their medication without consulting their healthcare provider.
For more information about the affected lot numbers and expiry dates, patients and healthcare providers should contact Accord Healthcare, Inc. or check the FDA's official recall notice.
The recalled product
- Product
- CINACALCET (CINACALCET)
- Brand
- CINACALCET
- Manufacturer
- ACCORD HEALTHCARE, INC.
- Hazard
- nitrosamine
- manufacturing-defect
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · CINACALCET
- HighFDA Recalls Cinacalcet 30mg Tablets for N-nitroso Impurity
FDA (Drugs) · 2024-12-11
- HighCinacalcet Tablets Recalled for N-Nitroso Impurity Exceeding FDA Safety Limit
FDA (Drugs) · 2024-12-11
- HighPrescription Cinacalcet Tablets Recalled for N-Nitroso Impurity
FDA (Drugs) · 2024-12-11
- HighCinacalcet tablets recalled for nitroso impurity above FDA limits
FDA (Drugs) · 2024-11-06
- HighCinacalcet tablets recalled for manufacturing impurity exceeding FDA limits
FDA (Drugs) · 2024-11-06
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27